{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:04:33Z","timestamp":1762002273489,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.eucr.2020.101261","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T08:29:35Z","timestamp":1590222575000},"page":"101261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis"],"prefix":"10.1016","volume":"33","author":[{"given":"Ashwin M.","family":"Raghavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zane C.","family":"Giffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham I.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eucr.2020.101261_bib1","doi-asserted-by":"crossref","first-page":"693964","DOI":"10.1155\/2011\/693964","article-title":"The natural history and outcomes of the patients with carcinosarcoma involving kidney and renal pelvis","volume":"2011","author":"Wang","year":"2011","journal-title":"Adv Urology"},{"issue":"1","key":"10.1016\/j.eucr.2020.101261_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3892\/ol.2014.2145","article-title":"Diagnosis and treatment of carcinosarcoma of the renal pelvis: a Case report.","volume":"8","author":"Dong","year":"2014","journal-title":"Oncology Lett"},{"issue":"14","key":"10.1016\/j.eucr.2020.101261_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl l_8","key":"10.1016\/j.eucr.2020.101261_bib4","article-title":"871PKEYNOTE-427 cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (CcRCC)","volume":"29","author":"McDermott","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eucr.2020.101261_bib5","article-title":"Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma","volume":"5 6","author":"Dal Molin","year":"2018","journal-title":"Gynecol Oncol Res Pract"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442020301492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442020301492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:57:55Z","timestamp":1762001875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442020301492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":5,"alternative-id":["S2214442020301492"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2020.101261","relation":{},"ISSN":["2214-4420"],"issn-type":[{"type":"print","value":"2214-4420"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2020.101261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101261"}}